doxazosin mesylate


Also found in: Dictionary, Thesaurus.
Related to doxazosin mesylate: Cardura

doxazosin mesylate

Cardozin XL (UK), Cardura, Cardura XL, Doxadura (UK)

Pharmacologic class: Sympatholytic, peripherally acting antiadrenergic

Therapeutic class: Antihypertensive

Pregnancy risk category C

Action

Blocks alpha1-adrenergic receptors, promoting vasodilation. Also reduces urethral resistance, relieving obstruction and improving urine flow and other symptoms of benign prostatic hypertrophy (BPH).

Availability

Tablets: 1 mg, 2 mg, 4 mg, 8 mg

Tablets (extended-release): 4 mg, 8 mg

Indications and dosages

Hypertension

Adults: 1 mg P.O. once daily. May increase dosage gradually q 2 weeks, up to 2 to 16 mg daily, as needed.

BPH

Adults: 1 mg P.O. once daily. May increase dosage gradually, up to 8 mg daily, as needed. Or, initially 4 mg (extended-release) P.O. daily. May increase dosage to 8 mg daily, as needed, at 3- to 4-week intervals.

Off-label uses

• Pheochromocytoma
• Syndrome X

Contraindications

• Hypersensitivity to drug, its components, or quinazoline derivatives

Precautions

Use cautiously in:
• renal or mild or moderate hepatic impairment, coronary insufficiency, or preexisting severe GI narrowing
• severe hepatic impairment (extended-release form not recommended)
• intraoperative floppy iris syndrome
• concurrent use of strong CYP3A4 inhibitor (such as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, or voriconazole), phosphodiesterase-5 (PDE-5) inhibitors
• elderly patients
• pregnant or breastfeeding patients (extended-release form not recommended in breastfeeding patients)
• children (safety not established).

Administration

• Give initial immediate-release dose at bedtime to minimize orthostatic hypotension and syncope.
• Give initial extended-release dose at breakfast.
• Be aware that extended-release tablets aren't indicated for hypertension.
• Be aware that prostate carcinoma should be ruled out before giving drug for BPH.
• Know that incidence of orthostatic hypotension increases greatly when daily dosage exceeds 4 mg and that it usually occurs within 6 hours of administration.

If new or worsening signs or symptoms of angina pectoris occur, discontinue drug.

Adverse reactions

CNS: dizziness, vertigo, headache, depression, drowsiness, fatigue, nervousness, weakness, asthenia

CV: orthostatic hypotension, chest pain, palpitations, tachycardia, arrhythmias

EENT: abnormal or blurred vision, conjunctivitis, epistaxis, rhinitis, pharyngitis

GI: nausea, vomiting, diarrhea, constipation, abdominal discomfort, flatulence, dry mouth

GU: decreased libido, sexual dysfunction

Respiratory: dyspnea

Musculoskeletal: joint pain, arthritis, gout, myalgia

Skin: flushing, rash, pruritus

Other: edema

Interactions

Drug-drug.Clonidine, nitrates, other antihypertensives: decreased antihypertensive effect

Drugs that reduce GI motility leading to markedly prolonged GI retention times (such as anticholinergics): increased systemic exposure to doxazosin

PDE-5 inhibitors: increased risk of symptomatic hypotension

Drug-diagnostic tests.Neutrophils, white blood cells: decreased counts

Drug-food.Any food: increased drug plasma Cmax (extended-release form)

Patient monitoring

• Monitor blood pressure with patient lying down and standing up every 2 to 6 hours after initial dose or after a dosage increase (when orthostatic hypotension is most likely to occur).

Patient teaching

• Tell patient to swallow extended-release tablets whole and not to chew, divide, cut, or crush them.
• Caution patient not to drive or perform other activities requiring alertness for 12 to 24 hours after first dose.
• Tell patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
• Advise patient to report episodes of dizziness or palpitations.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

doxazosin mesylate

(dŏk-sā′zə-sĭn)
n.
An alpha-blocker drug used to treat hypertension and benign prostatic hyperplasia.

doxazosin mesylate

Cardura® GI disease/urology A proton pump used for GERD, duodenal ulcers, hypersecretory conditions–eg, Zollinger-Ellison syndrome, BPH Adverse events Headache, asthenia, fever. See Benign prostatic hypertrophy, GERD.

doxazosin mesylate

(doksā´zōsin mes´ilāt´),
n brand name: Cardura;
drug class: peripheral α-adrenergic blocker;
action: peripheral blood vessels are dilated, peripheral re-sistance lowered;
uses: hypertension.
Mentioned in ?
References in periodicals archive ?
Doxazosin Mesylate is the generic equivalent to Pfizer Laboratories Cardura(R) Tablets, which is indicated for the treatment of hypertension and urinary outflow obstruction and obstructive and irritative symptoms associated with Benign Prostatic Hyperplasia (BPH).
With the final approval of doxazosin mesylate, Zenith Goldline has received nine final and two tentative approvals so far this year, with 27 additional ANDAs pending at the FDA," said Dr.
Doxazosin Mesylate is a product indicated for use in the treatment of urinary outflow obstruction and irritative symptoms associated with Benign Prostatic Hyperplasis (BPH), and for the treatment of general hypertension.
The 1mg, 2mg, 4mg and 8mg doxazosin mesylate tablets are the generic equivalent of Cardura(R) brand tablets marketed by Pfizer Inc.
IVAX Corporation (AMEX:IVX) today announced that the United States Food and Drug Administration (FDA) has given tentative approval to the company's Abbreviated New Drug Application (ANDA) for doxazosin mesylate in 1 mg, 2 mg, 4 mg, and 8 mg tablet strengths.